Clinical Psychopharmacology · Paper A
Antidepressant discontinuation
Stopping an antidepressant abruptly, especially a short half-lifeThe time it takes for the amount of a drug in the body to fall by half.Read more → drug, produces a distinct discontinuation syndromeWithdrawal-like symptoms that follow suddenly stopping a drug such as an antidepressant.Read more → that is often mistaken for something more serious. A patient who stops paroxetine suddenly can, within two days, develop dizziness, 'electric shock' sensations, and irritability. This rapid, days-long onset is the clue that distinguishes discontinuation from a depressive relapse.
Short half-lifeThe time it takes for the amount of a drug in the body to fall by half.Read more → agents like paroxetine and venlafaxine produce prominent discontinuation symptoms: dizziness, electric-shock or 'zap' sensations, tingling, nausea, vivid dreams, irritability and flu-like symptoms; remembered by the mnemonic FINISH (Flu-like, Insomnia, Nausea, Imbalance, Sensory disturbance, Hyperarousal). The syndrome is self-limiting and resolves rapidly if the drug is restarted. This differs from depressive relapse, which develops more slowly and centres on core mood symptoms, and from serotonin syndromeA dangerous reaction from too much serotonin activity, causing agitation, high temperature, and muscle overactivity.Read more →, which is caused by adding a serotonergicRelating to serotonin, a brain chemical involved in mood.Read more → drug rather than stopping one. Fluoxetine's long half-life gives a self-tapering effect, so it rarely causes noticeable discontinuation symptoms. A patient who stops venlafaxine abruptly and, within a day, reports zap sensations and flu-like aching typically finds these resolve within hours of restarting the same dose: e.g. a same-day restart settling symptoms that felt alarming overnight. Clinically, a rapid, days-long timeline plus quick resolution on restarting is what confirms discontinuation, not a depressive relapse. The proposed neurochemical mechanism is chronic adaptive downregulation: SSRISelective serotonin reuptake inhibitor, a common type of antidepressant.Read more → (selective serotonin reuptake inhibitor) treatment, in particular, produces reduced sensitivityThe proportion of people who truly have a condition that a test correctly identifies as positive.Read more → of serotonin receptors and transporter function over time. Stopping abruptly then causes a rapid fall in synaptic serotonin that this downregulated system cannot immediately compensate for, producing the discontinuation symptoms. Gastrointestinal symptoms such as diarrhoea are also a recognised feature of the syndrome, alongside the more classically remembered zaps and dizziness. Severity can be tracked with a validated instrument, the Discontinuation-Emergent Signs and Symptoms (DESS) checklist. Discontinuation of some antidepressants, particularly paroxetine and venlafaxine, has also been associated with emergent suicidal thoughts, a further reason to taper rather than stop abruptly.
A fresh doctor might see dizziness and irritability after stopping an antidepressant and reach straight for "relapse." Discontinuation symptoms are common, self-limiting, and entirely different from relapse: but only if you read the TIMING correctly. Hold the phrase DAYS NOT WEEKS through every section below; it is the single fact this whole topic hangs on.
Antidepressant is a cluster of symptoms that appears within days of stopping or rapidly reducing an antidepressant, most prominent with short drugs. It is NOT dependence (the drug is not craved or misused) and NOT relapse (the original depressive or anxiety illness has not necessarily returned): it is a physiological adjustment reaction to the sudden absence of the drug.
A common mistake is treating any new symptom after an antidepressant change as automatically "just discontinuation." The DAYS NOT WEEKS rule matters precisely because a slower-onset, mood-dominant picture should make you reconsider relapse instead. Restarting the old drug should genuinely resolve true discontinuation symptoms within a day or so: if it doesn't, the working diagnosis needs revisiting, not just more reassurance.
Imagine two patients stopping their antidepressant on the same day: one on paroxetine (a short HALF-LIFE (the time it takes blood levels of a drug to fall by half) ), one on fluoxetine (an unusually long half-life SSRI). The paroxetine patient can develop symptoms within a day or two, because blood levels fall quickly. The fluoxetine patient often notices nothing at all, because fluoxetine and its clear the body so slowly that the taper effectively happens on its own. This single principle (shorter half-life, more abrupt symptoms) explains almost every drug-specific detail in this topic.
The FINISH mnemonic captures the main features: Flu-like symptoms (aches, chills), Insomnia (often with vivid dreams), Nausea, Imbalance (dizziness, light-headedness), Sensory disturbances (the characteristic "electric shock" or "brain zap" sensations, plus tingling), and Hyperarousal (anxiety, irritability, agitation). Symptoms typically begin within one to three days of stopping or a significant dose reduction and are usually mild to moderate, though they can be distressing enough that patients present to an emergency department.
Discontinuation symptoms begin rapidly (days) after stopping and resolve rapidly (often within 24 hours) if the same drug is restarted at the same dose: this rapid resolution is itself a useful bedside test. Depressive relapse, by contrast, develops more gradually over weeks and centres on core mood symptoms (low mood, , hopelessness) rather than the physical, sensory symptoms of discontinuation. is the opposite scenario entirely: it results from ADDING or combining drugs, not stopping one, and presents with , , and fever rather than dizziness and zaps.
Paroxetine and venlafaxine, both short agents, are the drugs most associated with prominent discontinuation symptoms, unlike fluoxetine, whose long half-life makes clinically noticeable discontinuation rare. Suspect depressive relapse instead when symptoms build gradually over weeks, centre on mood rather than physical sensations, and do not resolve within a day of restarting the drug. Suspect instead when the trigger was starting or combining drugs, not stopping one, and the picture includes , and fever rather than dizziness and brain zaps. A withdrawal-mimicking organic cause, e.g. a viral illness or vestibular problem, is worth a moment's thought if the timing doesn't fit any of the three psychiatric explanations.
There is no blood test or scan for ; it is diagnosed clinically from the history. Three things build the diagnosis: a clear temporal link (symptoms starting within one to three days of stopping or reducing the dose), a FINISH-pattern symptom cluster, and, the most useful confirmatory step, rapid resolution after restarting the same drug at the same dose. If a patient's "relapse" resolves within 24 to 48 hours of restarting their , that speed of response all but confirms discontinuation rather than true relapse, since a genuine depressive relapse would not lift that fast. Screening questions should always exclude an alternative organic cause and check the timeline doesn't better fit relapse or before the label is applied.
NICE-aligned practice (NICE guideline NG222 on depression in adults) favours a gradual taper rather than abrupt cessation, particularly for short half-life agents like paroxetine and venlafaxine. Some patients need a slower, sometimes HYPERBOLIC TAPER (reducing the dose by a shrinking percentage each step, rather than equal fixed steps) if a standard linear taper still provokes symptoms. Management of an established discontinuation reaction is generally reassurance, and if symptoms are significant, restarting the same drug and tapering more slowly next time: not starting an unrelated new medication and not assuming the underlying illness has returned. Patients should be counselled about the possibility of these symptoms before they ever start a short half-life antidepressant, not only after they occur; that single conversation prevents a lot of unnecessary emergency presentations.
Vignettes often describe a patient stopping paroxetine or venlafaxine abruptly and developing dizziness and "electric shocks" within a day or two: the expected answer is , not or relapse. Another trap describes symptoms emerging gradually over several weeks with low mood as the dominant feature: the expected recognition is depressive relapse rather than discontinuation. A further trap tests whether you know fluoxetine's long makes it the least likely to cause a noticeable discontinuation reaction.
If symptoms start within days of stopping a short antidepressant and vanish within a day of restarting it, that's discontinuation, not relapse.